FRI0279 Current Immunosuppressive Drugs Are Not Enough To Treat The Pulmonary Involvement of Connective Tissue Diseases

• Published in: Annals of the rheumatic diseases Vol. 75; no. Suppl 2; p. 536
• Main Authors: Yazisiz, V., Oygen, S., Erbasan, F., Arslan, G., Gökalp, E., Tazegül, G., Avci, A.B., Terzioğlu, E.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2016
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2016-eular.3715

BackgroundInterstitial lung diseases (ILDs) may occur secondary to connective tissue diseases (CTDs) and increase morbidity and mortality due to ventilation impairment.ObjectivesTo reveal clinical, laboratory and imaging features of CTD -ILDs and to analyze treatment approaches.MethodsOne hundred thirty two consecutive patients were included in this cohort. Demographic characteristics, laboratory and HRCT results and treatment results were analyzed. More than 10% increase of pulmonary function tests were categorized as improvement, >10% decrease were categorized as deterioration and ±10% changes were categorized as stable disease.ResultsThere were 111 ILD patients (86.5% CTD-ILD) with follow-up time for more than 6 months. Median follow up time was 48 (Min-Max:6–260) months and mean age was 54.5±11.9 years. HRCT scan was repeated in median 3 (1–10) times per patients, with median 12.5 month intervals. The most frequent HRCT findings were ground-glass opacities, interlobular septal thickening and honeycomb patterns. 89.6% of CTD-ILD patients recieved corticosteroids and 44.8% recieved hydroxylchloroquine sulphate. Azathioprine and cyclophosphamide were the most common used immunosupresive drugs. Eighty four patients recieved at least one immunosuppressive agent. There were only 2 patients treated with four different immunosuppressive drugs. After treatment, mean pulmonary function tests did not significanty differ from baseline (p>0.05) (Table). 35% of the patients improved forced vital capacity(FVC >%10 increase) by treatment whereas 31% had decreased and 34% were stable.ConclusionsIt is not detected to have significant improvement by current immunosuppressive drugs in patients with CTD-ILDs. There is need more effective novel drugs to treat for CTD-ILD.Disclosure of InterestNone declared